Table 1.
Subject No. |
Gender | Age at Presentation |
Phosphorus at Presentation |
Intact FGF23 at Presentation |
Disease-Related Complications |
---|---|---|---|---|---|
1 | Female | 29 | 1.5 | 1242 | Pain, weakness, fractures1, osteomalacia on biopsy |
22 | Female | 31 | 1.6 | 92 | Rickets (childhood presentation), weakness, amputation2 |
3 | Female | 41 | 1.2 | 734 | Pain, low bone mineral density3 |
4 | Male | 50 | 2 | 329 | Weakness, fractures, ankle edema4, muscle atrophy |
5 | Male | 46 | 1.8 | 355 | Fractures, falls |
65 | Male | 51 | 1.8 | 88 | Pain, fractures, weakness |
7 | Male | 61 | 1.6 | 890 | Pain, fractures, osteomalacia on biopsy |
8 | Male | 59 | 2 | 132 | Pain, weakness |
9 | Male | 50 | 1.6 | 1684 | Pain, muscle atrophy, weight loss, osteomalacia on biopsy |
106 | Male | 46 | 1.2 | 84 | Weakness, pain, fractures |
11 | Male | 57 | 2.1 | 473 | Pain, low bone mineral density |
12 | Male | 50 | 1.6 | 119 | Pain, weakness, gait abnormality, low bone mineral density |
13 | Male | 39 | 1.8 | 1113 | Ankle edema, pain, difficulty ambulating, fractures |
14 | Female | 55 | 1.2 | 406 | Fractures, pain, low bone mineral density |
15 | Male | 44 | 1.6 | 353 | Pain, fractures, stiffness, low bone mineral density |
16 | Male | 44 | 1.8 | 95 | Fractures, weakness, muscle atrophy |
17 | Male | 33 | 2.2 | 146 | Pain, weakness, fractures |
18 | Male | 17 | 1.6 | 110 | Pain, fractures, low bone mineral density |
19 | Male | 37 | 1.8 | 290 | Pain |
20 | Female | 51 | 1.2 | 472 | Weakness, pain |
21 | Female | 47 | 1.9 | 1029 | Pain, fractures |
22 | Female | 62 | 2.0 | 156 | Fatigue, pain, fractures, low bone mineral density |
23 | Male | 67 | 1.4 | 1344 | Pain, weakness, ankle edema, fractures, low bone mineral density |
24 | Female | 18 | 1.4 | 76 | Pain, weakness, myalgia, fractures, weight loss |
25 | Male | 59 | 1.3 | 345 | Pain |
26 | Female | 14 | 1.6 | 177 | Ankle edema, pain, fractures, weakness, muscle spasms |
27 | Male | 57 | 2.1 | 294 | Weakness, pain, falls, cramps, tetany |
28 | Female | 66 | 1.6 | 2742 | Falls, fractures, weakness, pain, fatigue |
29 | Male | 48 | 2 | 482 | Pain, fatigue, height loss |
30 | Female | 49 | 1.9 | 535 | Fractures, weakness, fatigue, pain, stiffness, gait abnormality |
317 | Male | 50 | 1.8 | 81 | Fractures, fatigue, pain, muscle spasms, low bone mineral density |
M:F | 20:11 | Reference Range: 2.5-4.8 mg/dl |
Reference Range: 10-50 pg/ml |
||
Mean | 48.5 | 1.7 | 337 | ||
Median | 47 | 1.69 | 546.4 | ||
Range | 14-67 | 1.2-2.2 | 76-2742 |
Most common fracture locations included ribs/clavicle, femur/pelvis, followed by back/vertebral compression fractures leading to height loss. Fractures were often characterized as “slow-healing”.
Subject previously treated outside and presented to NIH with metastatic disease following persistent disease after amputation
Low bone mineral density refers to either a Z-score of ≤ −2.0 when the study was performed at NIH or as reported in referral data.
Ankle edema (bilateral or unilateral) was an unexplained, but surprisingly common finding among patients who otherwise had no evidence of heart failure or renal insufficiency.
Subject previously treated outside, presented to NIH with recurrent disease, and eventually developed pulmonary metastases
Subject previously treated outside and presented to NIH locally persistent
Patient presented with clinical features consistent with Cowden syndrome however PTEN mutation testing was negative.